C R Lines

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi request reprint A comparison of visual analog scale and categorical ratings of headache pain in a randomized controlled clinical trial with migraine patients
    C R Lines
    Merck and Co, Inc, P O Box 4, West Point, PA 19486, USA
    Pain 93:185-90. 2001
  2. ncbi request reprint Rizatriptan: pharmacological differences from sumatriptan and clinical results
    C R Lines
    Merck Research Laboratories, West Point, PA, USA
    Curr Med Res Opin 17:s54-8. 2001
  3. ncbi request reprint Telephone screening for amnestic mild cognitive impairment
    Christopher R Lines
    Merck Research Laboratories, West Point, PA, USA
    Neurology 60:261-6. 2003
  4. ncbi request reprint Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe
    Anup K Majumdar
    Merck Research Laboratories, West Point, PA 19422, USA
    Clin Pharmacol Ther 74:150-6. 2003
  5. doi request reprint Age effects on placebo response rates in clinical trials of acute agents for migraine: pooled analysis of rizatriptan trials in adults
    T W Ho
    Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Cephalalgia 29:711-8. 2009
  6. doi request reprint Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial
    J J Sevigny
    Merck Research Laboratories, North Wales, PA 19454, USA
    Neurology 71:1702-8. 2008
  7. ncbi request reprint Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine
    T W Ho
    Merck Research Laboratories, UG 4C 18, PO Box 1000, North Wales, PA 19454 1099, USA
    Neurology 70:1304-12. 2008
  8. ncbi request reprint Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study
    S A Reines
    Merck Research Laboratories, 10 Sentry Parkway, Blue Bell, PA 19422, USA
    Neurology 62:66-71. 2004
  9. ncbi request reprint Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone
    Jacqueline B McCrea
    Merck Research Laboratories, Bluebell, PA 19422, USA
    Clin Pharmacol Ther 74:17-24. 2003
  10. ncbi request reprint A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment
    Leon J Thal
    University of California, San Diego, CA, USA
    Neuropsychopharmacology 30:1204-15. 2005

Collaborators

Detail Information

Publications11

  1. ncbi request reprint A comparison of visual analog scale and categorical ratings of headache pain in a randomized controlled clinical trial with migraine patients
    C R Lines
    Merck and Co, Inc, P O Box 4, West Point, PA 19486, USA
    Pain 93:185-90. 2001
    ..Use of the VAS imposed additional administrative burdens. These findings suggest that the 4GS may be the preferred scale for assessing headache pain in clinical trials involving adult migraineurs...
  2. ncbi request reprint Rizatriptan: pharmacological differences from sumatriptan and clinical results
    C R Lines
    Merck Research Laboratories, West Point, PA, USA
    Curr Med Res Opin 17:s54-8. 2001
    ..The most common side-effects on both drugs occurred in <10% of patients and consisted of dizziness, drowsiness, and asthenia/fatigue. The adverse events were usually mild or moderate in severity and short-lasting...
  3. ncbi request reprint Telephone screening for amnestic mild cognitive impairment
    Christopher R Lines
    Merck Research Laboratories, West Point, PA, USA
    Neurology 60:261-6. 2003
    ....
  4. ncbi request reprint Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe
    Anup K Majumdar
    Merck Research Laboratories, West Point, PA 19422, USA
    Clin Pharmacol Ther 74:150-6. 2003
    ..The effect of aprepitant on in vivo CYP3A4 activity in humans with oral midazolam used as a sensitive probe of CYP3A4 activity was evaluated in this study...
  5. doi request reprint Age effects on placebo response rates in clinical trials of acute agents for migraine: pooled analysis of rizatriptan trials in adults
    T W Ho
    Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Cephalalgia 29:711-8. 2009
    ..Age appeared to be an important predictor of placebo response rate in rizatriptan trials, with older patients being less likely to respond to placebo and more likely to respond to rizatriptan...
  6. doi request reprint Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial
    J J Sevigny
    Merck Research Laboratories, North Wales, PA 19454, USA
    Neurology 71:1702-8. 2008
    ..We examined whether the growth hormone secretagogue MK-677 (ibutamoren mesylate), a potent inducer of IGF-1 secretion, slows the rate of progression of symptoms in patients with AD...
  7. ncbi request reprint Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine
    T W Ho
    Merck Research Laboratories, UG 4C 18, PO Box 1000, North Wales, PA 19454 1099, USA
    Neurology 70:1304-12. 2008
    ..To determine an effective and tolerable dose of a novel oral calcitonin gene-related peptide (CGRP) receptor antagonist, MK-0974, for the acute treatment of migraine...
  8. ncbi request reprint Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study
    S A Reines
    Merck Research Laboratories, 10 Sentry Parkway, Blue Bell, PA 19422, USA
    Neurology 62:66-71. 2004
    ..This study sought to evaluate the effect of rofecoxib, a nonsteroidal anti-inflammatory drug that selectively inhibits cyclo-oxygenase-2, in slowing the progression of dementia in patients with established AD...
  9. ncbi request reprint Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone
    Jacqueline B McCrea
    Merck Research Laboratories, Bluebell, PA 19422, USA
    Clin Pharmacol Ther 74:17-24. 2003
    ..The effects of aprepitant on the these 2 corticosteroids were evaluated...
  10. ncbi request reprint A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment
    Leon J Thal
    University of California, San Diego, CA, USA
    Neuropsychopharmacology 30:1204-15. 2005
    ..In conjunction with the lack of effects observed in previous AD studies, the findings suggest that inhibition of COX-2 is not a useful therapeutic approach in AD...
  11. ncbi request reprint Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial
    Paul S Aisen
    Georgetown University Medical Center, Washington, DC, USA
    Curr Alzheimer Res 5:73-82. 2008
    ..The significance of the observation that rofecoxib increased the rate of conversion from MCI to AD remains uncertain...